Objective: To explore and analyze the efficacy of low-dose mifepristone in the treatment of endometriosis. Methods: 56 patients with endometriosis who were diagnosed and treated in the gynecology department of the People’s Hospital of Danyang between August 2020 to December 2022 were recruited and divided into the study group (n = 28) and control group (n = 28). The study group was treated with low-dose mifepristone, and the control group was treated with regular-dose mifepristone. The effective rate of medication, hormone levels, bone density, and adverse reactions were compared between the groups. Results: There was a statistically significant difference (P < 0.05) in the effective rates of medication between the study group and the control group. Before treatment, the hormone levels were not statistically significant between the groups (P > 0.05); after treatment, the hormone levels in the study group were significantly better than those in the control group (P < 0.05). Before treatment, there was no significant difference in bone mineral density between the groups (P > 0.05); after treatment, bone density in the study group was higher than that in the control group (P < 0.05). The incidence of adverse reactions in the study group was significantly lower than that in the control group (P <
0.05). Conclusion: Low-dose mifepristone has a significant curative effect in the treatment of endometriosis, the hormone level and bone density are better, and there are few adverse drug reactions. This treatment is worthy of widespread promotion and application.
Zhang D, Ma S, Li L, 2023, Based on the PI3K/Akt/eNOS Pathway Analysis, the Mechanism of Danshou Decoction Regulating Endometriosis by Targeting miR-146a-5p. Chinese Medical Journal, 38(8): 1725–1731.
Zhang Y, Lin T, He T, et al., 2023, Based on the CXCL12/CXCR4 Axis, to Explore the Mechanism of Huber Powder Containing Medicated Serum to Promote the Autophagy Activity of Menstrual Blood-Derived Mesenchymal Stem Cells in Patients with Endometriosis. Drugs Evaluation Research, 46(7): 1424–1430.
Wang C, Gao T, 2023, The Effect of Triptorelin Combined with Laparoscopic Cystectomy in the Treatment of Endometriosis and Its Effect on the Levels of VEGF, IGF-1, sVCAM-1 and sICAM-1. Clinical Medicine Research and Practice, 8(19): 92–95.
Liu Y, Li Y, Hu H, et al., 2023, Study on the Correlation Between Serum Anti-Müllerian Hormone Level and Insulin Resistance in Patients with Endometriosis and Infertility. Laboratory Medicine and Clinic, 20(12): 1800–1802.
He Z, Li Y, 2023, The Effect of Dingkundan Combined with Mifepristone on the Levels of Pro-Angiogenic Growth Factors and Serum Tumor Markers in Postoperative Patients with Endometriosis. Chinese Modern Drug Application, 17(12): 108–111.
Yu C, Shi C, 2023, Comparison of the Clinical Effects of Kuntai Capsules and Estradiol Valerate Tablets in the Treatment of Perimenopausal Symptoms Caused by Postoperative GnRH-a in the Treatment of Endometriosis. Clinical Rational Drug Use, 16(16): 89–92.
Miao H, Miao C, Li N, et al., 2023, lncRNA HAND2-AS1 Inhibits the Migration and Invasion of Endometrial Stromal Cells in Patients with Endometriosis by Regulating the Expression of miR-21. Journal of Jilin University (Medical Edition), 49(3): 733–741.
Lin F, Wu Q, Wang R, et al., 2023, Effects of Pentoxifylline Combined with Ethinylestradiol and Cyproterone Tablets on Th1/Th2 Drift and Serum Anti-Endometrial Antibody and Vascular Endothelial Growth Factor Levels in Patients with Endometriosis Influence Discussion. Chinese Sex Science, 32(5): 76–80.
Shi L, Zou X, Zuo H. The Application Effect and Influencing Factors of GnRHa Combined with Different Drug Therapy in the Long-Term Management of Endometriosis After Operation. China Maternal and Child Health, 38(10): 1838–1843.
Liu H, Li L, Li H, et al., 2023, Changes and Correlation of PDGF and OPN Expression in Endometrial Tissue of Patients with Endometriosis. Chinese Maternal and Child Health, 38(9): 1556–1560.
Wang J, Xu C, 2023, Research on the Mechanism of Action of “Ghost Arrow Feather - Hedyotis diffusa” in the Treatment of Endometriosis Based on Network Pharmacology and Molecular Docking. Medical Information, 36(9): 21–29.
Mao J, Yu K, Bao Y, et al., 2023, Effects of Endometriosis on Embryonic Development and Clinical Outcomes in in vitro Fertilization or Intracytoplasmic Sperm Injection-Embryo Transfer Cycles. Chinese Journal of Health Inspection, 33(8): 958–961.
Huang J, Hu G, Zhang Y, et al., 2023, Observation on the Clinical Curative Effect of Yushen Huoxue Prescription Combined with Gonadotropin-Releasing Hormone Analogues in the Treatment of Kidney-Deficiency Endometriosis Infertility After Laparoscopic Surgery. Zhonghua Chinese Medicine Journal, 38(4): 1892–1896.
Liang H, Zhou X, Hu M, et al., 2023, Effects of Dienogest and GnRH Agonist Drugs on Serum Carbohydrate Antigen 125, Bone Mineral Density, Estradiol and Tumor Size in Patients Undergoing Endometriosis Surgery. Chinese Sex Science, 32(3): 54–58.
Huang L, Zhang Z, Du Y, et al., 2023, Effect of Goserelin Acetate Combined with Medroxyprogesterone on Soluble Human Leukocyte Antigen-G, E-Cadherin in Patients with Endometriosis. Clinical Military Medical Journal, 51(3): 315–317 + 320.